By the Top Tier Newswire AI Desk · August 17, 2026 at 9:35 AM ET · reviewed against 11 wire stories
ARGENX SE ADR (ARGX) is up +13.16% in the latest session. Our newswire has captured 11 stories on ARGX across 6 sources in the last 36 hours, with AI sentiment reading bullish (avg 66/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
ARGX stock surged 13.16% to $963.35 in early trading after positive topline results from the Phase 3 ALKIVIA trial of efgartigimod for autoimmune myositis. The trial met its primary endpoint and showed statistically significant and clinically meaningful improvement in patients, including those without existing treatment options. Piper Sandler raised the price target for the stock to $1,215 from $1,075, reinforcing the positive sentiment.
What Happened
The ALKIVIA Phase 3 trial enrolled 175 patients and demonstrated that efgartigimod delivered durable and multidimensional improvements. Patients with immune-mediated necrotizing myopathy (IMNM) improved by 14.8 points over placebo. The results were announced by Argenx and Zai Lab and are expected to be presented at an upcoming medical meeting. The drug, marketed as Vyvgart, is now the first Phase 3 therapy to show such outcomes in a condition with no approved treatments. The announcement triggered a strong market reaction, with the stock opening with a 10.3% gap up and reaching a session high of $966.28.
What The Data Shows
The stock opened at $939.00 and traded as high as $966.28 within the first five minutes of the session. Volume was 0.0M shares, below the 3-month average. The stock has traded within a 52-week range of $644.63 to $953.58 and hit four fresh 52-week highs on August 17. The company’s fundamentals show a market cap of $54.3B, a P/E of 30.9, and a revenue increase of 70.3% in the trailing twelve months. Net margins remain strong at 32.3%.
What To Watch
Argenx has no scheduled earnings date in the immediate future. Investors will likely monitor the breadth of analyst coverage and the presentation of full trial data at the upcoming medical meeting for further clarity on the drug’s potential.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ARGX · Aug 17 session (5-min) · +16.04% vs prior close · updated 8:58 PM ETAI sentiment, last 36h · averaged over 11 stories · 66/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
27d agoMarketChameleonBULLISH 73Product/PR
ARGX's Efgartigimod Achieves Significant Breakthrough for Patients with Autoimmune Myositis in ALKIVIA Phase 3 Trial
The ALKIVIA Phase 3 trial results reveal that efgartigimod from argenx yields significant, sustained improvement for autoimmune myositis patients—including those with no existing therapy—offering new hope in treating this challenging disease.
27d agoThe FlyBULLISH 63Analyst
Argenx price target raised to $1,215 from $1,075 at Piper Sandler
27d agoThe FlyNEUTRAL 50General
Zai Lab and Argenx announce results from Alkivia Phase 3 study
27d agoStockTitanBULLISH 73Product/PR
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
The Phase 3 study enrolled 175 patients; IMNM patients improved 14.8 points over placebo, with detailed results to be presented at an upcoming medical meeting.
27d agoThe FlyBULLISH 73Product/PR
Argenx announces ALKIVIA study meets primary endpoint
27d agoMorningstarBULLISH 71Product/PR
Argenx Shares Rise After Positive Results From Phase 3 Study of Efgartigimod
"The patient response to efgartigimod was durable and multidimensional: separation from placebo emerged early and held through a full year of treatment, with a treatment effect of comparable magnitude in immune-mediated necrotizing myopathy and dermatomyositis," Chief Medical Officer Luc Truyen said.
27d agoSeeking AlphaBULLISH 73Product/PR
Argenx advances as Vyvgart hits key trial endpoints for autoimmune myositis
Argenx (ARGX) stock surged after a successful Vyvgart trial in autoimmune myositis.
27d agoMorningstarNEUTRAL 52General
U.S. Futures, European Stocks Mixed
In Europe, the Stoxx Europe 600 climbed 0.2% in morning trading. Accelleron Industries rose 8.5% and argenx rose 8.4%. On the other hand, SIG Group slipped 22.1%, and Johnson Matthey dropped 4.7%. The FTSE 100 added 0.3%. Other stocks in Europe were mixed as France's CAC 40 decreased 0.1% and Germany's DAX was flat.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →